347 Views

Plenary

Session: Plenary Session 3: Real-World Data for Precision Medicine: A Pharmacoepidemiological Perspective

Real-World Data for Precision Medicine: A Pharmacoepidemiological Perspective

Tuesday, April 25, 2023

9:00 AM – 10:45 AM GMT

Moderator(s)

Maurizio Sessa, PharmD

Assistant Professor
University of Copenhagen
Kobenhavn O, Denmark
Vincent Lo Re, III, MD, MSCE (he/him/his)

Associate Professor of Medicine and Epidemiology
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania, United States

Speaker(s)

Andrew Bate

VP & Head, Safety Innovation & Analytics, Global Safety
GlaxoSmithKline, United States
Larus S. Gudmundsson (he/him/his)

Associate Professor
University of Iceland
Reykjavik, Iceland
David O. Arnar

Professoe
University of Iceland

Disclosure(s):

Maurizio Sessa, PhD: No financial relationships to disclose

Vincent Lo Re, MD, MSCE, FISPE, III: No financial relationships to disclose

Larus S. Gudmundsson: No financial relationships to disclose

David O. Arnar: No relevant disclosure to display

The COVID-19 pandemic has pushed forward research on tailor treatment and interventions to unique individual or population-level traits complementing conventional pharmacoepidemiological approaches. In this session, we will showcase precision medicine and precision public health approaches used for pharmacoepidemiological safety and effectiveness surveillance.

9:00-9:30: Use of post-approval data for real time personalized safety monitoring
Andrew Bate, Vice president, Head of Safety Innovation & Analytics, GSK

9:30-10:00: Safety monitoring in general practice: insights from Iceland on benzodiazepine’ and opioids’ risk
Larus S Gudmundsson, associate professor, University of Iceland

10:00-10:30: Precision Medicine using real-world data: a focus on cardiovascular therapy.
David O Arnar, Professor of Cardiology, University of Iceland

10:30-10:45: Discussion